3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
14
Phase EARLY_PHASE1
2
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Head & Neck
2
Breast
2
Tumor-Agnostic
1
Other
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
1
Interventions
Carboplatin
8
Paclitaxel
7
Fluorouracil
7
Cisplatin
7
atezolizumab
5
Trastuzumab
5
Pemetrexed
5
Oxaliplatin
5
Leucovorin
5
Bevacizumab
5
pembrolizumab
4
Gemcitabine
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
Surveys and Questionnaires
3
Observation
3
Leuprolide
3
Irinotecan
3
Glutamine
3
Drug Therapy
3
Docetaxel
3
Dexamethasone
3
130-nm albumin-bound paclitaxel
3
trifluridine tipiracil drug combination
2
regorafenib
2
osimertinib
2
enzalutamide
2
Surgical Procedures, Operative
2
Standard of Care
2
Sorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Methods
×
Tumor-Agnostic
×
Clear all
NCT01272024
2016-06-15
TEAMS
Yale University
Phase 3
Completed
146 enrolled